Issue 47, 2024

Breakthrough in cancer therapy: lutetium texaphyrin–celecoxib conjugate for immune and photodynamic treatment

Abstract

Immuno-photodynamic therapy (IPDT) has become a promising approach for cancer treatment. Innovative photosensitizers are essential to fully realize the potential of IPDT, specifically the complete elimination of tumors without recurrence. In this context, Jong Seung Kim et al. introduce a small molecule photosensitizer conjugate, LuCXB. This IPDT agent combines a celecoxib (cyclooxygenase-2 inhibitor) moiety with a near-infrared absorbing lutetium texaphyrin photocatalytic core. In aqueous solutions, the two components of LuCXB self-associate through inferred donor–acceptor interactions. As a result of this intramolecular association, LuCXB generates superoxide radicals (O2˙) via a type I photodynamic pathway upon irradiation with 730 nm light. This serves as a primary defense against the tumor and enhances the IPDT effect. For in vivo applications, they developed a CD133-targeting, aptamer-functionalized exosome-based nanophotosensitizer (Ex-apt@LuCXB) aimed at targeting cancer stem cells. Ex-apt@LuCXB demonstrated excellent photosensitivity, satisfactory biocompatibility, and strong tumor-targeting capabilities. Under photoirradiation, Ex-apt@LuCXB amplifies IPDT and produces significant antitumor effects in liver and breast cancer mouse models. The therapeutic outcomes are attributed to a synergistic mechanism that combines antiangiogenesis with photoinduced cancer immunotherapy.

Graphical abstract: Breakthrough in cancer therapy: lutetium texaphyrin–celecoxib conjugate for immune and photodynamic treatment

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Highlight
Submitted
08 Sep 2024
Accepted
06 Oct 2024
First published
07 Oct 2024
This article is Open Access
Creative Commons BY license

J. Mater. Chem. B, 2024,12, 12136-12138

Breakthrough in cancer therapy: lutetium texaphyrin–celecoxib conjugate for immune and photodynamic treatment

Q. Ding, Y. Wang, P. Zhang and L. Mei, J. Mater. Chem. B, 2024, 12, 12136 DOI: 10.1039/D4TB02019G

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements